Incyclix Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate INX-315 in Combination with Verzenio® (abemaciclib) and Fulvestrant in HR+/HER2- Breast Canc...
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Combination therapy to be evaluated as part of ongoing Phase 1/2 study in patients with HR+/HER2- metastatic breast cancer Incyclix will sponsor the trial and Lilly will provide Verzenio Incyclix plans to initiate combination cohorts with INX-315 in fourth quarter of 2024 RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and resistant cancer, today announced a clinical trial collaboration and supply agreement with Eli Lilly and Company (Lilly) for supply of its CDK4/6 inhibitor Verzenio® (abemaciclib) for use in combination with INX-315 and fulvestrant for treatment of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer who progressed on a prior CDK4/6i regimen. “We are pleased to enter this clinical trial collaboration with Lilly as it mar
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Global Clinical Trials Connect Conference 2025: Collaboration, Innovation and Enhancing Quality in Clinical Trials (London, United Kingdom - May 28-29, 2025) [Yahoo! Finance]Yahoo! Finance
- Is Now a Good Time to Buy the Dip in Eli Lilly Stock? [Yahoo! Finance]Yahoo! Finance
- Analysis-Wall Street awaits Amgen weight-loss drug data expected to move shares [Yahoo! Finance Canada]Yahoo! Finance Canada
- Analysis-Wall Street awaits Amgen weight-loss drug data expected to move shares [Yahoo! Finance]Yahoo! Finance
- Type 2 Diabetes Pipeline Landscape Research 2024: Comprehensive Insights About 75+ Companies and 80+ Drugs [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 10/30/24 - Miss
LLY
Sec Filings
- 11/20/24 - Form 4
- 11/20/24 - Form 4
- 11/20/24 - Form 4
- LLY's page on the SEC website